Nebivolol Increases Atrial Natriuretic Peptide/Systolic Blood Pressure Ratio in Hypertensive Patients

The aim of this study is to evaluate the medium term treatment effects of the beta-blocker nebivolol on the endogenous anti-hypertensive and anti-inflammatory agent Atrial Natriuretic Peptide (ANP) plasma levels in patients with moderate uncomplicated essential hypertension. The drug was given orally for 30 days to 25 patients. The daily dose was 5 mg once every morning. Quantitative determination of ANP was made by Radioimmunoassay (RIA). At the end of this clinical trial, plasma ANP levels showed a statistically non significant tendency to increase by 10.99% while both systolic (SBP) and diastolic (DBP) blood pressure as well as the diameters of the left cardiac cavities showed a statistically significant decrease. What was interesting was the fact that there was a statistically significant increase of 44.7% in the ratio ANP/SBP following the reduction of arterial blood pressure. This increase was the most important and essential finding as it indicated a real increase of ANP plasma levels. This result was obtained even though pressure and afterload, the homologous mechanical stimulatory parameters for ANP secretion, of the left cavities were diminished. These findings provide strong indications which were supported by several previous trials, that the increase in plasma ANP following the administration of beta-adrenergic blockers to hypertensive patients was a primary effect of beta blockade and not a mechanical one secondary to a negative inotropic action on the left ventricle. This primary action contributed to the anti-hypertensive effect of nebivolol during this trial